Document Detail


Platelet reactivity in coronary ostial blood: a reflection of the thrombotic state accompanying plaque rupture and of the adequacy of anti-thrombotic therapy.
MedLine Citation:
PMID:  11729369     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Optimal anti-thrombotic therapy for acute coronary syndromes (ACS) should suppress pro-thrombotic activity at the site of plaque rupture. We sought to determine whether platelet reactivity is increased in blood in the immediate vicinity of a ruptured plaque and is apparent even when blood is obtained by sampling from a catheter placed proximal to the lesion. METHODS: Blood was obtained from a catheter placed in the aorta and from the same catheter after engaging the culprit coronary artery. Platelet reactivity was determined with the use of flow cytometry by surface expression of P-selectin. RESULTS: In preliminary studies we demonstrated that a marker of thrombin activity, fibrinopeptide A, was similarly increased in blood taken from the coronary sinus and coronary arterial ostium of patients with ACS. Subsequently blood was obtained from the aorta and coronary arterial ostium through a coronary guide catheter for assessment of platelet reactivity in 23 subjects with ACS and 22 subjects with stable angina. The percentage of platelets expressing P-selectin in response to 0.2 microM adenosine diphosphate (ADP) was greater in coronary arterial samples from patients with ACS (aorta=6.1+/-1%, coronary artery=8.8+/-1.6%, p=0.02) compared with that in patients with stable symptoms (aorta=6.9+/-1.2, coronary artery=6.5+/-1.4, p=NS). CONCLUSIONS: Coronary arterial blood obtained from the ostium through a coronary guide catheter can be used to determine whether thrombin activity and platelet reactivity are increased in the immediate vicinity of a ruptured atherosclerotic plaque. The simplicity of the approach developed should facilitate its use in future studies designed to determine the impact of optimal suppression of platelet reactivity and the pro-thrombotic state before coronary interventions on short- and long-term clinical outcomes.
Authors:
S S Kabbani; M W Watkins; P A Holoch; E F Terrien; B E Sobel; D J Schneider
Related Documents :
3307369 - Imbalance among t-cell subsets in patients with coronary arterial aneurysms in kawasaki...
10832619 - 3d assessment of myocardial perfusion parameter combined with 3d reconstructed coronary...
21539609 - Management of radial artery perforation complicating coronary intervention: a stepwise ...
18159099 - Asymptomatic acute ischemic stroke after primary percutaneous coronary intervention in ...
20707759 - Ticagrelor for the treatment of arterial thrombosis.
21235629 - The le-compte's maneuver for relief of bronchial compression in atrial septal defect.
16095979 - Alpha-1b adrenoceptors mediate neurogenic constriction in mesenteric arteries of normot...
21785969 - Mesa: the nih-sponsored study that validates atherosclerosis imaging for primary preven...
20594489 - Rheolytic thrombectomy of acute stent thrombosis of cervical vertebral artery. case rep...
Publication Detail:
Type:  Journal Article    
Journal Detail:
Title:  Journal of thrombosis and thrombolysis     Volume:  12     ISSN:  0929-5305     ISO Abbreviation:  J. Thromb. Thrombolysis     Publication Date:  2001 Oct 
Date Detail:
Created Date:  2001-11-30     Completed Date:  2002-10-18     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  9502018     Medline TA:  J Thromb Thrombolysis     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  171-6     Citation Subset:  IM    
Affiliation:
The University of Vermont, Burlington, VT, USA.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acute Disease
Aged
Aorta
Case-Control Studies
Coronary Artery Disease / complications*,  pathology
Coronary Circulation*
Coronary Vessels
Fibrinolytic Agents / administration & dosage
Fibrinopeptide A / metabolism
Humans
Male
Middle Aged
P-Selectin / blood
Platelet Activation* / drug effects
Rupture, Spontaneous / blood*,  etiology
Thrombophilia / blood,  etiology
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; 0/P-Selectin; 25422-31-5/Fibrinopeptide A

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Ecarin clotting time but not aPTT correlates with PEG-hirudin plasma activity.
Next Document:  Sulfonylureas are not associated with increased mortality in diabetics treated with thrombolysis for...